» Articles » PMID: 32749716

Natural History of Multiple Sulfatase Deficiency: Retrospective Phenotyping and Functional Variant Analysis to Characterize an Ultra-rare Disease

Abstract

Multiple sulfatase deficiency (MSD) is an ultra-rare neurodegenerative disorder caused by pathogenic variants in SUMF1. This gene encodes formylglycine-generating enzyme (FGE), a protein required for sulfatase activation. The clinical course of MSD results from additive effect of each sulfatase deficiency, including metachromatic leukodystrophy (MLD), several mucopolysaccharidoses (MPS II, IIIA, IIID, IIIE, IVA, VI), chondrodysplasia punctata, and X-linked ichthyosis. While it is known that affected individuals demonstrate a complex and severe phenotype, the genotype-phenotype relationship and detailed clinical course is unknown. We report on 35 cases enrolled in our retrospective natural history study, n = 32 with detailed histories. Neurologic function was longitudinally assessed with retrospective scales. Biochemical and computational modeling of novel SUMF1 variants was performed. Genotypes were classified based on predicted functional change, and each individual was assigned a genotype severity score. The median age at symptom onset was 0.25 years; median age at diagnosis was 2.7 years; and median age at death was 13 years. All individuals demonstrated developmental delay, and only a subset of individuals attained ambulation and verbal communication. All subjects experienced an accumulating systemic symptom burden. Earlier age at symptom onset and severe variant pathogenicity correlated with poor neurologic outcomes. Using retrospective deep phenotyping and detailed variant analysis, we defined the natural history of MSD. We found that attenuated cases can be distinguished from severe cases by age of onset, attainment of ambulation, and genotype. Results from this study can help inform prognosis and facilitate future study design.

Citing Articles

Preclinical use of a clinically-relevant scAAV9/SUMF1 vector for the treatment of multiple sulfatase deficiency.

Presa M, Bailey R, Ray S, Bailey L, Tata S, Murphy T Commun Med (Lond). 2025; 5(1):29.

PMID: 39870870 PMC: 11772666. DOI: 10.1038/s43856-025-00734-9.


Bone marrow transplantation reverses metabolic alterations in multiple sulfatase deficiency: a case series.

Pillai N, Liu N, Li X, Li X, Ahrens-Nicklas R, Adang L Commun Med (Lond). 2025; 5(1):12.

PMID: 39789203 PMC: 11718225. DOI: 10.1038/s43856-024-00703-8.


Complementarity of biomarker screening and genetic analyses based on the case of an attenuated multiple sulfatase deficiency.

Lipinski P, Lugowska A, Pollak A, Ploski R, Tylki-Szymanska A J Appl Genet. 2025; .

PMID: 39776369 DOI: 10.1007/s13353-024-00936-2.


Bone marrow transplantation increases sulfatase activity in somatic tissues in a multiple sulfatase deficiency mouse model.

Presa M, Pham V, Ray S, Piec P, Ryan J, Billings T Commun Med (Lond). 2024; 4(1):215.

PMID: 39448727 PMC: 11502872. DOI: 10.1038/s43856-024-00648-y.


Hematopoietic stem cell gene therapy improves outcomes in a clinically relevant mouse model of multiple sulfatase deficiency.

Pham V, Tricoli L, Hong X, Wongkittichote P, Castruccio Castracani C, Guerra A Mol Ther. 2024; 32(11):3829-3846.

PMID: 39169621 PMC: 11573602. DOI: 10.1016/j.ymthe.2024.08.015.


References
1.
Groeschel S, Kuhl J, Bley A, Kehrer C, Weschke B, Doring M . Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Juvenile Metachromatic Leukodystrophy Compared With Nontransplanted Control Patients. JAMA Neurol. 2016; 73(9):1133-40. DOI: 10.1001/jamaneurol.2016.2067. View

2.
Helman G, Van Haren K, Bonkowsky J, Bernard G, Pizzino A, Braverman N . Disease specific therapies in leukodystrophies and leukoencephalopathies. Mol Genet Metab. 2015; 114(4):527-36. PMC: 4390468. DOI: 10.1016/j.ymgme.2015.01.014. View

3.
Cosma M, Pepe S, Annunziata I, Newbold R, Grompe M, Parenti G . The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell. 2003; 113(4):445-56. DOI: 10.1016/s0092-8674(03)00348-9. View

4.
Hong X, Kumar A, Daiker J, Yi F, Sadilek M, De Mattia F . Leukocyte and Dried Blood Spot Arylsulfatase A Assay by Tandem Mass Spectrometry. Anal Chem. 2020; 92(9):6341-6348. PMC: 7203001. DOI: 10.1021/acs.analchem.9b05274. View

5.
Dierks T, Schmidt B, Borissenko L, Peng J, Preusser A, Mariappan M . Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell. 2003; 113(4):435-44. DOI: 10.1016/s0092-8674(03)00347-7. View